CompletedPhase 2NCT00072345

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Studying Uveal melanoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Wen-Jen Hwu, MD, PhD, MD, PhD
Memorial Sloan Kettering Cancer Center
Intervention
lomustine(drug)
Eligibility
18 years · All sexes
Timeline
2003

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00072345 on ClinicalTrials.gov

Other trials for Uveal melanoma

Additional recruiting or active studies for the same condition.

See all trials for Uveal melanoma →

← Back to all trials